## **Listing of Claims**

1. - 48. (Cancelled)

49. (Currently amended) A method of delivering a therapeutic or an antigenic protein or peptide to an individual comprising:

administering to the individual an effective amount of a chimaeric virus comprising a heterologous nucleic acid sequence encoding the therapeutic or the antigenic protein or peptide wherein the nucleic acid sequence is under control of an expression control sequence, or a vector system, a host cell, or a pharmaceutical composition thereof, wherein the chimaeric virus is produced by a method comprising culturing a host cell which comprises one or more Simian Immunodeficiency Virus (SIV) Gag-Pol nucleic acid sequences encoding an SIV eapsid under control of an expression control sequence, wherein said SIV Gag-Pol nucleic acid sequences encode an SIV capsid, and which further comprises a vector comprising a Human Immunodeficiency Virus type 2 (HIV-2) packaging signal and the heterologous nucleic acid sequence; wherein said culturing results in said vector being packaged in the SIV capsid to produce the chimaeric virus.

50. (Previously presented) The method according to claim 49 wherein the individual is a human or non-human primate.

51. – 56. (Cancelled)